Crossmark

Correction: Phase 2 study of oral thalidomide-cyclophosphamide-dexamethasone for recurrent/refractory adult Langerhans cell histiocytosis

Crossref DOI link: https://doi.org/10.1038/s41375-023-01812-4

Published Online: 2023-02-08

Published Print: 2023-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wang, Ji-nuo https://orcid.org/0000-0003-4036-7547
Liu, Ting

Zhao, Ai-lin

Pan, Bo-ju

Sun, Jian

Li, Jian https://orcid.org/0000-0002-4549-0694
Zhou, Dao-bin https://orcid.org/0000-0002-1592-1932
Cao, Xin-xin https://orcid.org/0000-0001-7884-3073
Duan, Ming-hui https://orcid.org/0000-0003-2130-6300
License Information

Text and Data Mining valid from 2023-02-08

Version of Record valid from 2023-02-08
More Information

Article History

First Online: 8 February 2023

Free to read: This content has been made available to all.